Der Internist

, Volume 49, Issue 5, pp 570–580 | Cite as

Hormontherapie und Anti-Aging

Gibt es eine Indikation?
  • D. Heutling
  • H. LehnertEmail author
Schwerpunkt: Hormontherapie


Der Wunsch nach einem langen Leben ist tief in den meisten Menschen verwurzelt. Erfreulicherweise hat die Lebenserwartung in den letzten Jahrzehnten deutlich zugenommen. Auf der anderen Seite aber ist ein fortgeschrittenes Alter mit einer Zunahme der Morbidität verbunden. Daher ist es notwendig, Strategien zu entwickeln, die über eine alleinige Lebensverlängerung hinausgehend zu einer Anhebung der Lebensqualität im Alter führen. Verschiedene Substanzen, welche Alterungsprozesse bremsen sowie Krebs- und degenerativen Erkrankungen vorbeugen sollen, sind Gegenstand wissenschaftlicher Untersuchungen. Insbesondere Hormonen wird eine Anti-Aging-Wirkung zugeschrieben. Diese Übersicht stellt die hierzu vorliegenden Studiendaten vor.


Anti-Aging Hormontherapie DHEA Wachstumshormon Melatonin 

Hormone therapy and anti-aging: is there an indication?


The desire for a long life is deeply embedded in nearly all men. Fortunately life expectancy has remarkably increased over the past decades, on the other hand advancing age is frequently associated with a rise in morbidity. Above simply prolonging life there is a need to search for strategies to improve the quality of life in the elderly. Different substances to prevent premature aging, cancer and degenerative disorders appear to be promising candidates. Since it has been suggested that the decline of different hormones over the lifespan is closely related to the aging process replacement of these hormones may be a strategy against aging. Especially hormones like growth hormone, DHEA, testosterone and melatonin were considered as anti-aging agents.

This review is focusing on the theoretical background and the previously known effects of different hormones to slow aging processes. Despite some promising results in a variety of studies conducted over the past years presently available data do not justify the broad use of hormones for anti-aging purposes. However, although no single hormone can be recognized as a ‘rejuvenating’ and life extending agent, some of their actions may be beneficial for the aging process.


Anti-aging Hormone replacement DHEA Growth hormone Melatonin 



Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Literatur (Auswahl)

  1. 1.
    Abdu TA, Neary R, Elhadd TA et al. (2001) Coronary risk in growth hormone deficient hypopituitary adults: increased predicted risk is due largely to lipid profile abnormalities. Clin Endocrinol (Oxf) 55: 209–216Google Scholar
  2. 2.
    Anisimov VN, Zavarzina NY, Zabezhinski MA et al. (2001) Melatonin increases both life span and tumor incidence in female CBA mice. J Gerontol A Biol Sci Med Sci 56: B311–B323PubMedGoogle Scholar
  3. 3.
    Arlt W, Callies F, Koehler I et al. (2001) Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion. J Clin Endocrinol Metab 86: 4686–4692PubMedCrossRefGoogle Scholar
  4. 4.
    Bates AS, Van’t Hoff W, Jones PJ, Clayton RN (1996) The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 81: 1169–1172PubMedCrossRefGoogle Scholar
  5. 5.
    Baulieu EE, Thomas G, Legrain S et al. (2000) Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci U S A 97: 4279–4284PubMedCrossRefGoogle Scholar
  6. 6.
    Bengtsson BA, Koppeschaar HP, Abs R et al. (1999) Growth hormone replacement therapy is not associated with any increase in mortality. KIMS Study Group. J Clin Endocrinol Metab 84: 4291–4292PubMedCrossRefGoogle Scholar
  7. 7.
    Blask DE, Dauchy RT, Sauer LA (2005) Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal. Endocrine 27: 179–188PubMedCrossRefGoogle Scholar
  8. 8.
    Cohn L, Feller AG, Draper MW et al. (1993) Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF-I concentrations. Clin Endocrinol (Oxf) 39: 417–425Google Scholar
  9. 9.
    Dean CE (2000) Prasterone (DHEA) and mania. Ann Pharmacother 34: 1419–1422PubMedGoogle Scholar
  10. 10.
    Elhadd TA, Abdu TA, Clayton R (2001) Hypopituitarism and atherosclerosis. Ann Med 33: 477–485PubMedCrossRefGoogle Scholar
  11. 11.
    Feldman HA, Goldstein I, Hatzichristou DG et al. (1994) Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151: 54–61PubMedGoogle Scholar
  12. 12.
    Ferrari E, Cravello L, Falvo F et al. (2008) Neuroendocrine features in extreme longevity. Exp Gerontol 43: 88–94PubMedCrossRefGoogle Scholar
  13. 13.
    Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL et al. (1999) Dehydroepiandrosterone replacement in aging humans. J Clin Endocrinol Metab 84: 1527–1533PubMedCrossRefGoogle Scholar
  14. 14.
    Hankinson SE (2005) Endogenous hormones and risk of breast cancer in postmenopausal women. Breast Dis 24: 3–15PubMedGoogle Scholar
  15. 15.
    Hennessey JV, Chromiak JA, DellaVentura S et al. (2001) Growth hormone administration and exercise effects on muscle fiber type and diameter in moderately frail older people. J Am Geriatr Soc 49: 852–858PubMedCrossRefGoogle Scholar
  16. 16.
    Herxheimer A, Petrie KJ (2002) Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev 2: CD001520PubMedGoogle Scholar
  17. 17.
    Heutling D, Lehnert H (2005) Hormone therapy and menopause. Dtsch Med Wochenschr 130: 829–834PubMedCrossRefGoogle Scholar
  18. 18.
    Huppert FA, Van Niekerk JK (2001) Dehydroepiandrosterone (DHEA) supplementation for cognitive function. Cochrane Database Syst Rev 4: CD000304Google Scholar
  19. 19.
    Iranmanesh A, Lizarralde G, Veldhuis JD (1991) Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab 73: 1081–1088PubMedGoogle Scholar
  20. 20.
    Iwasaki Y, Asai M, Yoshida M et al. (2004) Dehydroepiandrosterone-sulfate inhibits nuclear factor-kappaB-dependent transcription in hepatocytes, possibly through antioxidant effect. J Clin Endocrinol Metab 89: 3449–3454PubMedCrossRefGoogle Scholar
  21. 21.
    Jankowski CM, Gozansky WS, Schwartz RS et al. (2006) Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: a randomized, controlled trial. J Clin Endocrinol Metab 91: 2986–2993PubMedCrossRefGoogle Scholar
  22. 22.
    Jenkins PJ (2006) Cancers associated with acromegaly. Neuroendocrinology 83: 218–223PubMedCrossRefGoogle Scholar
  23. 23.
    Johansson T, Le GP (2005) The effect of dehydroepiandrosterone sulfate and allopregnanolone sulfate on the binding of [(3)H]ifenprodil to the N-methyl-d-aspartate receptor in rat frontal cortex membrane. J Steroid Biochem Mol Biol 94: 263–266PubMedCrossRefGoogle Scholar
  24. 24.
    Kawano H, Yasue H, Kitagawa A et al. (2003) Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. J Clin Endocrinol Metab 88: 3190–3195PubMedCrossRefGoogle Scholar
  25. 25.
    Kostoglou-Athanassiou I, Treacher DF, Wheeler MJ, Forsling ML (1998) Melatonin administration and pituitary hormone secretion. Clin Endocrinol (Oxf) 48: 31–37Google Scholar
  26. 26.
    Kroboth PD, Salek FS, Pittenger AL et al. (1999) DHEA and DHEA-S: a review. J Clin Pharmacol 39: 327–348PubMedCrossRefGoogle Scholar
  27. 27.
    Labrie F, Diamond P, Cusan L et al. (1997) Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab 82: 3498–3505PubMedCrossRefGoogle Scholar
  28. 28.
    Labrie F, Luu-The V, Labrie C, Simard J (2001) DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology. Front Neuroendocrinol 22: 185–212PubMedCrossRefGoogle Scholar
  29. 29.
    Legrain S, Massien C, Lahlou N et al. (2000) Dehydroepiandrosterone replacement administration: pharmacokinetic and pharmacodynamic studies in healthy elderly subjects. Clin Endocrinol Metab 85: 3208–3217CrossRefGoogle Scholar
  30. 30.
    Lemus-Wilson A, Kelly PA, Blask DE (1995) Melatonin blocks the stimulatory effects of prolactin on human breast cancer cell growth in culture. Br J Cancer 72: 1435–1440PubMedGoogle Scholar
  31. 31.
    Leonsson M, Hulthe J, Oscarsson J et al. (2002) Intima-media thickness in cardiovascularly asymptomatic hypopituitary adults with growth hormone deficiency: relation to body mass index, gender, and other cardiovascular risk factors. Clin Endocrinol (Oxf) 57: 751–759Google Scholar
  32. 32.
    Li L, Yu H, Schumacher F et al. (2003) Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States). Cancer Causes Control 14: 721–726PubMedCrossRefGoogle Scholar
  33. 33.
    Liu D, Dillon JS (2002) Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3). J Biol Chem 277: 21379–21388PubMedCrossRefGoogle Scholar
  34. 34.
    Markowitz JS, Carson WH, Jackson CW (1999) Possible dihydroepiandrosterone-induced mania. Biol Psychiatry 45: 241–242PubMedCrossRefGoogle Scholar
  35. 35.
    Mattison JA, Lane MA, Roth GS, Ingram DK (2003) Calorie restriction in rhesus monkeys. Exp Gerontol 38: 35–46PubMedCrossRefGoogle Scholar
  36. 36.
    Morales AJ, Haubrich RH, Hwang JY et al. (1998) The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf) 49: 421–432Google Scholar
  37. 37.
    Morales AJ, Nolan JJ, Nelson JC, Yen SS (1994) Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 78: 1360–1367PubMedCrossRefGoogle Scholar
  38. 38.
    Nair KS, Rizza RA, O’Brien P et al. (2006) DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 355: 1647–1659PubMedCrossRefGoogle Scholar
  39. 39.
    Orentreich N, Brind JL, Rizer RL, Vogelman JH (1984) Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 59: 551–555PubMedGoogle Scholar
  40. 40.
    Orentreich N, Brind JL, Vogelman JH et al. (1992) Long-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men. J Clin Endocrinol Metab 75: 1002–1004PubMedCrossRefGoogle Scholar
  41. 41.
    Papadakis MA, Grady D, Black D et al. (1996) Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med 124: 708–716PubMedGoogle Scholar
  42. 42.
    Paparrigopoulos T (2002) Melatonin response to atenolol administration in depression: indication of beta-adrenoceptor dysfunction in a subtype of depression. Acta Psychiatr Scand 106: 440–445PubMedCrossRefGoogle Scholar
  43. 43.
    Percheron G, Hogrel JY, Denot-Ledunois S et al. (2003) Effect of 1-year oral administration of dehydroepiandrosterone to 60- to 80-year-old individuals on muscle function and cross-sectional area: a double-blind placebo-controlled trial. Arch Intern Med 163: 720–727PubMedCrossRefGoogle Scholar
  44. 44.
    Reiter WJ, Pycha A, Schatzl G et al. (1999) Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology 53: 590–594PubMedCrossRefGoogle Scholar
  45. 45.
    Reiter WJ, Schatzl G, Mark I et al. (2001) Dehydroepiandrosterone in the treatment of erectile dysfunction in patients with different organic etiologies. Urol Res 29: 278–281PubMedCrossRefGoogle Scholar
  46. 46.
    Rosen T, Bengtsson BA (1990) Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336: 285–288PubMedCrossRefGoogle Scholar
  47. 47.
    Roth GS, Lane MA, Ingram DK et al. (2002) Biomarkers of caloric restriction may predict longevity in humans. Science 297: 811PubMedCrossRefGoogle Scholar
  48. 48.
    Roth GS, Lesnikov V, Lesnikov M et al. (2001) Dietary caloric restriction prevents the age-related decline in plasma melatonin levels of rhesus monkeys. J Clin Endocrinol Metab 86: 3292–3295PubMedCrossRefGoogle Scholar
  49. 49.
    Rudman D, Feller AG, Nagraj HS et al. (1990) Effects of human growth hormone in men over 60 years old. N Engl J Med 323: 1–6PubMedGoogle Scholar
  50. 50.
    Sauer LA, Dauchy RT, Blask DE (2001) Melatonin inhibits fatty acid transport in inguinal fat pads of hepatoma 7288CTC-bearing and normal Buffalo rats via receptor-mediated signal transduction. Life Sci 68: 2835–2844PubMedCrossRefGoogle Scholar
  51. 51.
    Schwartz AG, Pashko LL (2004) Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev 3: 171–187PubMedCrossRefGoogle Scholar
  52. 52.
    Shi R, Yu H, McLarty J, Glass J (2004) IGF-I and breast cancer: a meta-analysis. Int J Cancer 111: 418–423PubMedCrossRefGoogle Scholar
  53. 53.
    Sonntag WE, Carter CS, Ikeno Y et al. (2005) Adult-onset growth hormone and insulin-like growth factor I deficiency reduces neoplastic disease, modifies age-related pathology, and increases life span. Endocrinology 146: 2920–2932PubMedCrossRefGoogle Scholar
  54. 54.
    Sousa A, Ticku MK (1997) Interactions of the neurosteroid dehydroepiandrosterone sulfate with the GABA(A) receptor complex reveals that it may act via the picrotoxin site. J Pharmacol Exp Ther 282: 827–833PubMedGoogle Scholar
  55. 55.
    Srinivasan V, Pandi-Perumal SR, Maestroni GJ et al. (2005) Role of melatonin in neurodegenerative diseases. Neurotox Res 7: 293–318PubMedCrossRefGoogle Scholar
  56. 56.
    Svensson J, Bengtsson BA, Rosen T et al. (2004) Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab 89: 3306–3312PubMedCrossRefGoogle Scholar
  57. 57.
    Taaffe DR, Jin IH, Vu TH et al. (1996) Lack of effect of recombinant human growth hormone (GH) on muscle morphology and GH-insulin-like growth factor expression in resistance-trained elderly men. J Clin Endocrinol Metab 81: 421–425PubMedCrossRefGoogle Scholar
  58. 58.
    Taaffe DR, Lewis B, Marcus R (1994) Quantifying the effect of hand preference on upper limb bone mineral and soft tissue composition in young and elderly women by dual-energy X-ray absorptiometry. Clin Physiol 14: 393–404PubMedCrossRefGoogle Scholar
  59. 59.
    Takebayashi M, Hayashi T, Su TP (2004) A perspective on the new mechanism of antidepressants: neuritogenesis through sigma-1 receptors. Pharmacopsychiatry 37 (Suppl 3): S208–S213PubMedCrossRefGoogle Scholar
  60. 60.
    Vacheron-Trystram MN, Cheref S, Gauillard J, Plas J (2002) A case report of mania precipitated by use of DHEA. Encephale 28: 563–566PubMedGoogle Scholar
  61. 61.
    Vesnushkin GM, Plotnikova NA, Semenchenko AI, Anisimov VN (2006) Dose-dependent inhibitory effect of melatonin on carcinogenesis induced by benzo[a]pyrene in mice. J Exp Clin Cancer Res 25: 507–513PubMedGoogle Scholar
  62. 62.
    Villareal DT, Holloszy JO (2004) Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. JAMA 292: 2243–2248PubMedCrossRefGoogle Scholar
  63. 63.
    Villareal DT, Holloszy JO (2006) DHEA enhances effects of weight training on muscle mass and strength in elderly women and men. Am J Physiol Endocrinol Metab 291: E1003–E1008PubMedCrossRefGoogle Scholar
  64. 64.
    Wallace JD, Cuneo RC, Baxter R et al. (1999) Responses of the growth hormone (GH) and insulin-like growth factor axis to exercise, GH administration, and GH withdrawal in trained adult males: a potential test for GH abuse in sport. J Clin Endocrinol Metab 84: 3591–3601PubMedCrossRefGoogle Scholar
  65. 65.
    Wetterberg L, Bergiannaki JD, Paparrigopoulos T et al. (1999) Normative melatonin excretion: a multinational study. Psychoneuroendocrinology 24: 209–226PubMedCrossRefGoogle Scholar
  66. 66.
    Wilson ST, Blask DE, Lemus-Wilson AM (1992) Melatonin augments the sensitivity of MCF-7 human breast cancer cells to tamoxifen in vitro. J Clin Endocrinol Metab 75: 669–670PubMedCrossRefGoogle Scholar
  67. 67.
    Wolkowitz OM, Kramer JH, Reus VI et al. (2003) DHEA treatment of Alzheimer’s disease: a randomized, double-blind, placebo-controlled study. Neurology 60: 1071–1076PubMedGoogle Scholar
  68. 68.
    Yu H, Rohan T (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92: 1472–1489PubMedCrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag 2008

Authors and Affiliations

  1. 1.Klinik für Nephrologie und HochdruckkrankheitenOtto-von-Guericke-Universität MagdeburgMagdeburgDeutschland
  2. 2.Medizinische Klinik IUniversitätsklinikum Schleswig-Holstein,Campus LübeckLübeckDeutschland
  3. 3.University HospitalWarwick Medical SchoolCoventryGreat Britain

Personalised recommendations